Medication & Implant Candidacy · MRONJ · Downey, CA
Dental Implants on Bisphosphonates: What MRONJ Risk Actually Means for You
Most patients on an oral osteoporosis medication can still get implants. Here is exactly how I figure out whether you are one of them.
2,000+ implants placed · founded 2010 · 238 reviews at 4.9 · physician coordination included
The Honest Bottom Line
Can you get dental implants if you take a bisphosphonate? Usually, yes. Here is how I decide.
If you take a bisphosphonate and you want a dental implant, the honest bottom line comes first: most patients on an oral bisphosphonate for osteoporosis, Fosamax (alendronate), Boniva (ibandronate), or Actonel (risedronate), can have implants safely. The disqualifier is almost never the osteoporosis itself. It is the specific drug, the route (oral versus IV), the dose (osteoporosis dose versus oncology dose), and how long you have been taking it. So before I say a word about surgery, I work out which of those categories you are actually in, rather than refusing you on sight the way a lot of offices do. The condition I screen for is MRONJ, medication-related osteonecrosis of the jaw, and for oral bisphosphonates at osteoporosis dosing the risk tied to implant surgery is meaningful but small, commonly cited well under 1%. IV and oncology dosing is a different, higher-risk conversation. This is general education from a Downey implant surgeon, not a direction to start or stop any medication. That decision is always made with your prescribing physician, with my surgical risk assessment in writing for them to weigh.
Which drug
Bisphosphonate vs denosumab
Oral vs IV
A pill is not an infusion
The dose
Osteoporosis vs oncology
How long
The 3 to 4 year mark
Mechanism
What bisphosphonates and denosumab actually do to jaw healing
Your bone is never static, it is in constant turnover, with osteoclasts resorbing old bone and osteoblasts laying down new bone in a continuous cycle. Antiresorptives deliberately suppress the osteoclasts to stop the bone loss that drives osteoporosis, which is genuinely what you want for fracture prevention. But that same suppression of remodeling means that when I open a surgical site in the jaw, the site rebuilds and heals more slowly afterward. The AAOMS position paper on medication-related osteonecrosis of the jaw lays this mechanism out as the basis for the whole risk.
Antiresorptives brake the demolition crew. Picture your jaw as a building under constant renovation, a demolition crew clearing the old and a build crew laying the new. These drugs slow the demolition crew, which is exactly why the bone keeps its density and resists fracture, but the same brake means a fresh surgical wound is renovated a little more slowly. The bone is dense, just slower to repair itself after I place an implant.
Why the jaw specifically, and not your hip or your wrist? Two reasons. The jaws remodel faster than most other bones in the body, so a brake on remodeling shows up here first. And the jaws are uniquely exposed to the bacteria of the mouth through the teeth, in a way no other bone is. Put a slower-healing bone next to a constant bacterial load and you have the one site where suppressed remodeling can turn into a healing problem. That is not inevitable, so I will not overstate it as if it were.
Hold one limit in mind as we go, and notice it is not a wall. Slower remodeling is not the same as no healing. In most oral-osteoporosis-dose patients the jaw still heals around an implant perfectly well, just with a little less margin than a patient on no drug at all, and that thinner margin is the entire reason technique and follow-up matter more in these cases than they do in a healthy mouth.
The antiresorptive family
Oral bisphosphonates
Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate)
IV bisphosphonates
Reclast (zoledronate) yearly for osteoporosis; Zometa (zoledronate) and Aredia (pamidronate) at oncology dose
Denosumab (RANK-ligand)
Prolia for osteoporosis, Xgeva at oncology dose. Not a bisphosphonate
Patients lump them together because all three slow bone turnover and raise the same healing concern, even though denosumab is a different kind of molecule.
Bisphosphonates bind into your bone and linger for years. Denosumab’s effect wanes over the dosing interval and reverses after you stop. That one difference drives the whole timing strategy.
The Risk, In Proportion
MRONJ, explained honestly (medication-related osteonecrosis of the jaw)
AAOMS diagnostic definition
MRONJ is jawbone that becomes exposed and then fails to heal, staying exposed for more than eight weeks, in a patient on an antiresorptive or antiangiogenic drug, who has no history of radiation to the jaw. All three parts, exposed non-healing bone past eight weeks, the antiresorptive medication, and no prior jaw radiation, have to be present for it to be MRONJ at all.
Now the absolute risk, stated proportionately so we neither frighten you nor wave it away. For oral bisphosphonates at osteoporosis dosing, the MRONJ risk associated with implant or oral surgery is commonly cited well under 1%, with AAOMS reporting roughly 0.02 to 0.05% in osteoporosis populations and the ADA citing a prevalence near 0.10%. That is higher than someone taking no drug at all, and it is still small in absolute terms. For IV or oncology-dose exposure the picture is substantially different, with reported risk running from the low single digits up toward roughly 10% depending on the drug and how long it has been used. Same disease family, very different numbers.
under 1%
oral, osteoporosis dose
to ~10%
IV, oncology dose
The real risk multipliers are worth naming so you can locate yourself honestly. Longer duration of therapy raises it, which is the three-to-four-year discussion again. IV raises it over oral. Oncology dose raises it over osteoporosis dose. And it stacks with other things: steroids taken at the same time, antiangiogenic cancer drugs, smoking, and uncontrolled diabetes. Two of those overlap so often with implant patients that I keep separate pages on them, one on dental implants with diabetes and one on dental implants for smokers, because the healing math compounds.
Here is where I want to correct the two opposite mistakes I watch patients run into. The first is that people take a sub-1% risk and inflate it in their heads into a near-certainty, then avoid treatment they actually need and could have had safely. The second is that many offices respond to that same small risk by refusing the patient outright, because saying no is easier than doing the assessment. My position is simply to do the work, to find where you genuinely fall on that spectrum and tell you, which is the honest middle these two failure modes skip.
One closing point, and I will not dress it up as a guarantee. MRONJ is uncommon, it is often manageable when it is caught early, and the cases you read about cluster around tooth extractions and IV oncology dosing far more than around a well-planned implant placed in a screened oral-bisphosphonate patient. I will never tell you that any protocol of mine eliminates the risk, because nothing does. Careful screening is how you keep it where it belongs, which is small.
Where You Actually Fall
Oral vs IV bisphosphonates vs denosumab: where you actually fall
Lumping every antiresorptive into one flat you-cannot-have-implants answer is the core mistake, because the route and the dose change the MRONJ risk by orders of magnitude, not by a little. Two patients can both say they take a bone drug and be in completely different risk worlds. The table puts the tiers side by side, ordered low to high so the eye lands on the reassuring tier first.
| Medication / class (brand + generic, route) | Typical indication & dose | Relative MRONJ risk for implant surgery | What I typically do |
|---|---|---|---|
| Oral bisphosphonate, osteoporosis dose: Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate), taken by mouth | Osteoporosis, oral daily, weekly, or monthly dosing | Low~0.02 to 0.10%Commonly well under 1%. AAOMS reports roughly 0.02 to 0.05% in osteoporosis populations; the ADA cites a prevalence near 0.10%. Elevated versus no drug, rising past roughly 3 to 4 years on therapy. Where most worried patients land. | Usually proceed after a full assessment and a coordination call with your physician. Consider a drug-holiday discussion only in longer-duration cases. |
| Denosumab (Prolia), injection under the skin | Osteoporosis, 60 mg every 6 months | Intermediatetenths of a percentSits between the oral and IV bisphosphonate tiers. Because its effect wanes over the dosing interval rather than lingering in bone, the strategy is timing, not stopping. | Often proceed, timing placement toward the later part of the 6-month interval, coordinated with the prescriber. Do NOT simply stop the drug, since stopping carries rebound bone-loss and fracture risk. |
| IV bisphosphonate, osteoporosis dose: Reclast (zoledronate), once yearly | Osteoporosis, once-yearly IV infusion | Moderatehigher than oral, well below oncologyAbove the oral pills, and clearly below oncology dosing. This row exists specifically so once-yearly Reclast-for-osteoporosis patients are never painted with the oncology tier. | Individualized with your physician, with added biologic support and a written surgical note. Not the hard pause reserved for active cancer-dose therapy. |
| IV bisphosphonate, oncology dose: Zometa (zoledronate), Aredia (pamidronate), by IV. Oncology-dose denosumab (Xgeva) belongs here too | Oncology dosing, monthly or near-monthly | Higherup to ~10%The highest-risk tier, reported from the low single digits up toward roughly 10% depending on the drug and how long it has been used. The only Coral on this page. | Individualize, and usually pause elective implants, managed directly with your oncologist. Frequently a non-surgical alternative during active treatment. |
| No antiresorptive | Not on a bisphosphonate or denosumab | Baselinereference rowStandard implant risk, the comparison anchor that lets the table communicate relative risk by tier rather than scary absolutes in isolation. | Standard protocol, with the same atraumatic technique and follow-up I use on every case. |
- Drug
- Oral bisphosphonate, osteoporosis dose: Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate), taken by mouth
- Dose
- Osteoporosis, oral daily, weekly, or monthly dosing
- MRONJ risk
- Commonly well under 1%. AAOMS reports roughly 0.02 to 0.05% in osteoporosis populations; the ADA cites a prevalence near 0.10%. Elevated versus no drug, rising past roughly 3 to 4 years on therapy. Where most worried patients land.
- What I do
- Usually proceed after a full assessment and a coordination call with your physician. Consider a drug-holiday discussion only in longer-duration cases.
- Drug
- Denosumab (Prolia), injection under the skin
- Dose
- Osteoporosis, 60 mg every 6 months
- MRONJ risk
- Sits between the oral and IV bisphosphonate tiers. Because its effect wanes over the dosing interval rather than lingering in bone, the strategy is timing, not stopping.
- What I do
- Often proceed, timing placement toward the later part of the 6-month interval, coordinated with the prescriber. Do NOT simply stop the drug, since stopping carries rebound bone-loss and fracture risk.
- Drug
- IV bisphosphonate, osteoporosis dose: Reclast (zoledronate), once yearly
- Dose
- Osteoporosis, once-yearly IV infusion
- MRONJ risk
- Above the oral pills, and clearly below oncology dosing. This row exists specifically so once-yearly Reclast-for-osteoporosis patients are never painted with the oncology tier.
- What I do
- Individualized with your physician, with added biologic support and a written surgical note. Not the hard pause reserved for active cancer-dose therapy.
- Drug
- IV bisphosphonate, oncology dose: Zometa (zoledronate), Aredia (pamidronate), by IV. Oncology-dose denosumab (Xgeva) belongs here too
- Dose
- Oncology dosing, monthly or near-monthly
- MRONJ risk
- The highest-risk tier, reported from the low single digits up toward roughly 10% depending on the drug and how long it has been used. The only Coral on this page.
- What I do
- Individualize, and usually pause elective implants, managed directly with your oncologist. Frequently a non-surgical alternative during active treatment.
- Drug
- No antiresorptive
- Dose
- Not on a bisphosphonate or denosumab
- MRONJ risk
- Standard implant risk, the comparison anchor that lets the table communicate relative risk by tier rather than scary absolutes in isolation.
- What I do
- Standard protocol, with the same atraumatic technique and follow-up I use on every case.
Population estimates from AAOMS and ADA guidance and peer-reviewed reviews. Your individual risk is set at consultation, not from this table.
Low · oral
Oral bisphosphonates at osteoporosis dose, the Fosamax, Boniva, and Actonel group, are the lowest antiresorptive risk tier, and for most worried patients this is exactly where they land. After a proper assessment and a quick coordination call with your physician, this is usually a green light, with the duration of therapy being the main thing that nudges the conversation.
Intermediate · denosumab
Denosumab (Prolia) at 60 mg under the skin every six months sits between the oral and IV bisphosphonate tiers. Because its effect wanes across the six-month window rather than lingering in the bone, a recognized strategy is to time the placement toward the later part of that interval. Active oncology-dose denosumab, Xgeva at 120 mg monthly, is a different matter and is generally a contraindication during treatment.
Moderate · IV osteoporosis
IV Reclast (zoledronate) given once a year for osteoporosis is higher risk than the oral pills but far lower than oncology dosing, and it gets handled as an individualized decision with your physician rather than the hard pause reserved for cancer-dose therapy.
Higher · IV oncology
IV zoledronate or Aredia (pamidronate) at oncology doses, especially with recent exposure, is the highest-risk tier there is, and that is usually a hard pause on elective implant surgery that I manage directly with your oncologist rather than working around. For these readers the honest next move is physician coordination first, and sometimes a non-surgical alternative until any cancer treatment is complete.
How I Work These Cases
How I assess and place these cases at 5D Smiles
Complete medication history
I need the exact drug name, oral or IV, brand versus generic, the dose, the date you started, the date of your last dose, and the indication, osteoporosis or oncology. A vague I take something for my bones is not enough to keep you safe, and I would rather ask the detailed questions than guess.
Physician coordination, in writing
Before I commit to anything, I contact your prescribing physician to confirm the regimen and talk through the case, and I put my implant-side risk assessment in writing. I never tell you to start or stop a medication. I give your physician the surgical risk picture so they can weigh it against your fracture risk.
Proven biologics: PRF / PRP + UV
These are supportive, not a guarantee, and never a MRONJ eliminator. PRF or PRP is your own blood, drawn the morning of surgery and concentrated for platelets, delivering your own growth factors into the site. UV photofunctionalization resets the titanium surface so bone cells adhere faster. You can read the surface science on my page about UV-activated implants, and how this fits the larger picture is on my page about how to prevent dental implant failure.
Atraumatic technique, conservative loading
Here the medication, not the disease, drives my choices. I minimize bone trauma during placement, use primary closure where indicated, extend the integration window so the implant is not asked to work too early, and stage the follow-up visits. The elevated MRONJ window is exactly the stretch the site sits partially healed, so the whole plan gets the bone through that stretch with as little stress as possible.
For the highest-risk healing cases · we discuss, we do not claim
For the hardest healers, the full-arch reconstructions, the patients with uncontrolled diabetes, the osteoporosis patients with a real antiresorptive history, I will tell you honestly where the science is heading, including emerging areas that are not yet proven or FDA-approved, so you have the full picture rather than a sales pitch. My actual protocol is built on the proven biologics above, the ones with human evidence behind them, and I keep the emerging material as a footnote rather than part of what I administer.
Honest and Still Debated
The drug-holiday question: honest and still debated
A drug holiday is a temporary, physician-directed pause of the antiresorptive before surgery, and sometimes for a stretch afterward, meant to let bone turnover partially recover before I place the implant. I want to say just as plainly that this is genuinely debated in the literature, and that it is not a blanket rule I apply to everyone who walks in on a bone drug.
The debate is worth telling honestly, using the framing from the people who actually set the guidance. For oral bisphosphonates, the AAOMS position paper discusses considering a holiday in longer-duration cases while openly acknowledging that the evidence a holiday meaningfully lowers MRONJ risk is limited. The ADA, in its guidance on osteoporosis medications and oral surgery, goes further and states there is insufficient evidence to recommend a holiday or a waiting period before dental treatment, and that you should not modify routine dental care solely because of osteoporosis antiresorptive medication. I cite both because the honest answer lives between them, and I am not going to pretend there is more certainty here than there is.
Why a generic holiday is the wrong tool for Prolia
Because Prolia’s effect reverses when you stop it, and because stopping it can trigger rebound bone loss and even fractures, you do not simply pause Prolia for dental work. Instead you time the dental work within the existing dosing cycle, in coordination with the prescriber. Anyone who tells a Prolia patient to just stop the shot for a few months before implants is giving dangerous advice.
Whose call is it, in the end? The prescribing physician’s, because they are the one weighing your fracture risk against a small surgical MRONJ risk, and only they know both sides of that scale. My job is to supply the implant-side risk assessment in writing, not to direct your medication. And one practical reassurance: most patients resume their medication after the early soft-tissue healing is done, rather than stopping it permanently, so a holiday where one is appropriate is usually a pause, not an ending.
So the honest close is this. A drug holiday helps in some longer-duration oral cases, it is the wrong tool entirely in others like Prolia, and it is always individualized with your physician rather than applied off a chart, which means anyone offering you a one-size pause rule is skipping the very assessment that keeps you safe.
What I Stand Behind
Biologics that support healing in suppressed bone
The evidence-based biologics are what actually carries these cases. PRF and PRP, your own concentrated platelets, and UV photofunctionalization, the reactivated titanium surface, are what I genuinely rely on to support osseointegration in bone the medication has suppressed. They have peer-reviewed evidence behind them in people, and I still hold the honest limit: they support healing, they do not eliminate MRONJ risk, and I would never claim otherwise. You can read the surface science on my page about UV-activated implants.
Where I Stand
“The osteoporosis is almost never the disqualifier. The medication is, and only some of them, at some doses, for some durations. For oral bisphosphonates at osteoporosis dosing the MRONJ risk tied to implant surgery is commonly well under 1%, meaningful but small, so I do the work to find out exactly where you fall instead of refusing you on sight. IV and oncology dosing is a different, higher-risk conversation I run with your oncologist. I am not here to promise that any protocol of mine erases that risk, because nothing does. I am here to screen it honestly, coordinate with your physician, and tell you the truth either way.”
Honest Stop-Points
Who I would not place, or would send to their physician first
Honest stop-points matter as much as honest green lights, so let me name concretely who gets a stop or a pause from me.
- Active IV oncology-dose bisphosphonates like Zometa or Aredia, or oncology-dose denosumab (Xgeva), during treatment.
- Recent high-dose IV exposure.
- Anyone with a prior MRONJ episode.
In those cases the risk is real, and the right move is to defer the elective surgery and manage it with your oncologist, not to work around it.
A stop from me is never abandonment. When I recommend against placement, you still leave with a documented alternative, usually a non-surgical path such as a snap-on or implant-free overdenture to restore your function until any oncology course is finished, plus my written reasoning for your physician. You do not walk out with a no and nothing else.
Then there are the send-to-your-physician-first cases, which are not stops but are not green lights yet either. Long-duration oral therapy stacked with other compounding risk factors, uncontrolled diabetes, heavy smoking, or steroids, is a case where I want the prescriber’s input, and possibly a holiday discussion, before I commit to a surgery date. Those compounding factors are why I keep separate honest pages on dental implants with diabetes and dental implants for smokers, because each one moves the same dial.
Let me state the principle in my own words, because it is the whole reason I built my practice the way I did. A surgeon who will tell you no when no is genuinely right is the same surgeon you can trust when the answer is finally yes. I am not interested in being the office that says yes to everything and sorts out the consequences in the chair.
So here is the calm next step. Bring your full medication list to a consult, the exact names, doses, and dates, and physician coordination is built into how I work it up. And if you are still uncertain, or you have already been turned away somewhere else, my pages on dental implants when you have been told no and on your real risk in real numbers are written for exactly that reader.
Bring your exact medication list. I will stratify your real risk.
If you take or took a bisphosphonate or denosumab and you have been told implants are off the table, let me do the actual work first. Bring the exact drug, dose, and dates, and I will stratify your real MRONJ risk, coordinate with your prescribing physician, and tell you honestly whether this is a green light, a pause, or a different path. Forty-five minutes with me in Downey, a 3D CBCT scan, and exact pricing in writing, with no upsell and no risk-talk saved for the chair. Single titanium implants start from $3,500; full-arch All-on-X starts at $20,000 per arch, all-inclusive.
Reserve your consultOr call (562) 923-4538
Questions, Answered Honestly
Bisphosphonates, denosumab, and implants: the questions I hear
I take Fosamax (alendronate). Can I still get a dental implant?
Almost certainly yes. Oral Fosamax for osteoporosis is the lowest antiresorptive risk tier, with an MRONJ risk tied to implant surgery commonly cited well under 1%. After I take a full medication history and place a quick coordination call to your physician, an oral-Fosamax case is usually a green light. The one variable I weigh hardest is how long you have been on it, since the conversation shifts around the three-to-four-year mark.
What is MRONJ, and how likely is it really if I am on a bisphosphonate?
MRONJ stands for medication-related osteonecrosis of the jaw: by the AAOMS definition, exposed jawbone that fails to heal past eight weeks, in a patient on an antiresorptive or antiangiogenic drug, with no history of jaw radiation. For oral bisphosphonates at osteoporosis dosing the risk tied to implant surgery is commonly well under 1% (AAOMS reports about 0.02 to 0.05%, the ADA a prevalence near 0.10%). For IV and oncology dosing it is substantially higher, into the low single digits up toward about 10%. It is uncommon, and often manageable when caught early.
Are bisphosphonates and Prolia (denosumab) the same thing for implant risk?
Not exactly, though patients reasonably lump them together. Both are antiresorptives that slow bone turnover, which is why both raise the MRONJ conversation, but denosumab (Prolia) is a RANK-ligand inhibitor, not a bisphosphonate. The practical difference is that bisphosphonates bind into bone and linger for years after your last dose, while denosumab's effect wanes over the dosing interval and reverses after you stop. That is why the timing strategy differs between the two.
Can I get dental implants if I am on Prolia (denosumab)?
Often yes, with the right timing. Prolia at the osteoporosis dose of 60 mg every six months sits at an intermediate risk, between the oral and IV bisphosphonate tiers, and because its effect wanes across the six-month window, a recognized strategy is to time the placement toward the later part of that interval with your prescriber. Importantly, you do not simply stop Prolia for surgery, since stopping it can trigger rebound bone loss and fractures. Active oncology-dose denosumab, Xgeva at 120 mg monthly, is a different situation and is generally a contraindication during treatment.
I take Reclast (zoledronate) for osteoporosis. Is that different from the IV bisphosphonates given for cancer?
Yes, very different, and the difference is the dose and the reason. Reclast (zoledronate) once a year for osteoporosis is an IV bisphosphonate, so it carries more risk than the oral pills, but far less than the same molecule at oncology doses. Zometa (zoledronate) and Aredia (pamidronate) at oncology dosing are the highest-risk tier. So your once-yearly osteoporosis Reclast is handled as an individualized decision with your physician, not the hard pause I apply to active cancer-dose IV therapy.
Does it matter how long I have been taking my bisphosphonate?
It matters a lot. Because bisphosphonates accumulate in bone, longer duration of therapy raises MRONJ risk, and roughly the three-to-four-year mark is where the AAOMS guidance and my own assessment start to shift. Someone who started an oral bisphosphonate last year is in a different place than someone eight years in. That is exactly why I ask for your start date and your last dose, not just the drug name.
Do I need a drug holiday before implant surgery, and is stopping my medication safe?
Maybe, and it depends entirely on your situation, which is why it is a physician's decision and not a blanket rule. A drug holiday is a temporary, physician-directed pause to let bone turnover partially recover. The AAOMS discusses considering one in longer-duration oral cases while acknowledging the evidence it meaningfully lowers risk is limited, and the ADA states there is insufficient evidence to recommend a holiday at all. Critically, you do not simply stop Prolia, because that carries rebound fracture risk. I supply your physician my written surgical risk assessment, and they weigh it against your fracture risk.
Will I have to stop my osteoporosis medication permanently to get implants?
Almost never. Where a pause is appropriate at all, it is usually temporary, and most patients resume their medication after the early soft-tissue healing is complete rather than stopping for good. The decision belongs to the physician managing your osteoporosis, because they know what stopping the drug would cost you in fracture risk. My role is to give them a clear picture of the implant-side risk so the two of you can weigh both.
I finished bisphosphonates a few years ago. Am I still at risk for MRONJ?
Possibly some, and this is where the drug you took matters. Bisphosphonates bind into your bone mineral and accumulate, so their effect can linger for years after your last dose, which means stopping a few years ago does not necessarily reset you to baseline. Denosumab is different, since its effect reverses after you stop. So when you stopped is a real question for a bisphosphonate, and I ask for the exact dates. In most former oral-osteoporosis-dose patients the residual risk is still small, but I screen for it rather than assume it is gone.
Why does the jaw specifically get osteonecrosis and not other bones?
Two reasons together single out the jaw. First, the jaws remodel faster than most other bones, so a drug that brakes remodeling shows its effect here before anywhere else. Second, the jaws are uniquely exposed to the bacteria of the mouth through the teeth, in a way your hip or wrist never is. Put slower-healing bone next to a constant bacterial load and an open surgical site, and the jaw becomes the one place where suppressed remodeling can turn into a non-healing wound. It is not inevitable, it is just why the jaw is the site of concern.
Do PRF, PRP, or UV-activated implants lower my MRONJ risk?
They support healing, and I am careful not to claim more than that. PRF and PRP use your own concentrated platelets to deliver growth factors into the site, and UV photofunctionalization resets the titanium surface so bone cells adhere faster, both of which help a slower-healing site integrate. But I will not tell you they eliminate MRONJ risk, because nothing does. What actually keeps the risk small is the screening, the physician coordination, the atraumatic technique, and the follow-up, with the biologics adding margin on top.
What if I am on an IV cancer-dose bisphosphonate or Xgeva and you decide not to place implants?
Then I tell you honestly, and you still leave with a plan, because a stop is never abandonment. For active IV oncology-dose bisphosphonates like Zometa or Aredia, or oncology-dose denosumab like Xgeva, elective implant surgery is usually deferred and managed with your oncologist, since the risk is genuinely elevated during treatment. When I recommend against placement, I give you a documented alternative, often a snap-on or implant-free overdenture to restore your function until any oncology course is complete, along with my written reasoning for your physician. You get a real path forward, not just a no.
What information should I bring to my consultation about my medication?
Bring the specifics, because I cannot stratify your risk without them. I need the exact drug name, whether you take it as a pill or by IV, brand versus generic, the dose, the date you started, the date of your most recent dose, and the indication, meaning osteoporosis or an oncology reason. The simplest thing is to bring your full medication list or the bottles themselves. The more precise you are on dates and dose, the more precisely I can place you on the risk spectrum.
Will you coordinate with my doctor before placing implants?
Yes, that is built into how I work these cases. I contact your prescribing physician to confirm your regimen and discuss the case, and I put my implant-side surgical risk assessment in writing for them. I never tell you to start or stop a medication, because that decision belongs to the physician weighing your fracture risk. What I do is make sure they have a clear picture of the surgical side, so both sides of the scale, your bones and your jaw, are weighed by the right person with full information.
How is this different from your dental implants and osteoporosis page?
This page is about the medication and the MRONJ question specifically, the drug, the route, the dose, and the duration, and where you fall across oral, IV, and denosumab. My dental implants and osteoporosis page is about the disease itself, including CTX bone-turnover testing and how I handle osteoporotic bone more broadly. There is overlap, since many patients have both the condition and the drug, but if your main worry is the medication and MRONJ, you are on the right page. For the wider candidacy picture, see my page on whether you are a candidate for dental implants.
Is it safe to get dental implants at all if I have osteoporosis and take a bone drug?
For most patients on an oral bisphosphonate for osteoporosis, yes, it is reasonably safe with proper screening, which is the honest bottom line of this whole page. Published reviews report implant survival in bisphosphonate patients of about 94% at five years, with one 2025 review finding no statistically significant difference in survival versus non-osteoporotic patients, though the same body of evidence does show a modestly higher relative failure risk that careful screening is meant to manage. The safety comes from doing the work: stratifying your exact medication and route, coordinating with your physician, using atraumatic technique, and following up closely. It is the IV and oncology-dose situations, not the osteoporosis pill, where I most often pause.
Keep Reading
Related, if more than one thing is in play
Dental Implants with Osteoporosis
The disease itself, including CTX bone-turnover testing and how I handle osteoporotic bone, the companion to this medication-focused page.
Am I a Candidate for Dental Implants?
The wider candidacy picture, weighing every factor together when more than one thing is in play beyond a single medication.
Dental Implants with Diabetes
How I support compromised healing when blood sugar is working against the bone, one of the factors that compounds MRONJ risk.
Dental Implants for Smokers
Why smoking raises the healing stakes, and how I work with smokers rather than turning them away, another compounding risk factor.
UV-Activated Implants Explained
The surface science behind one of the proven biologics I use to support integration in slower-healing bone.
How to Prevent Dental Implant Failure
The full picture of how I protect an implant in a compromised site, where the biologics and technique fit together.
Dental Implants When You've Been Told No
Written for the reader who has already been turned away somewhere else and is not sure the no was the final word.
Your Risk, in Real Numbers
An honest look at the actual numbers behind implant risk, for the patient who wants the math rather than reassurance.
References
- AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaw (2022 update): the MRONJ definition (exposed jawbone over 8 weeks, on an antiresorptive or antiangiogenic, no jaw radiation), oral-bisphosphonate MRONJ risk in osteoporosis populations (~0.02 to 0.05%) versus substantially higher IV and oncology risk, and drug-holiday consideration in longer-duration oral therapy with limited supporting evidence. American Association of Oral and Maxillofacial Surgeons (PubMed). Professional society position paper (specialty consensus, the highest available guidance for MRONJ).
- American Dental Association guidance on osteoporosis medications and oral surgery: insufficient evidence to recommend a drug holiday or waiting period for MRONJ prevention, and routine dental treatment should not be modified solely because of osteoporosis antiresorptive medication. American Dental Association. National professional association clinical guidance.
- Bisphosphonates and Dental Implants: A Systematic Review and Meta-Analysis (Materials, 2023): estimated implant survival in bisphosphonate patients of 94.2% at 5 years and 90.1% at 10 years, alongside a modestly higher relative failure risk versus non-bisphosphonate patients. PubMed Central (NIH). Systematic review and meta-analysis (peer-reviewed).
- Impact of Osteoporosis on Dental Implant Survival (Journal of Clinical Medicine, 2025 systematic review and meta-analysis): no statistically significant difference in implant survival between osteoporotic and non-osteoporotic patients, supporting comparable survival in controlled osteoporosis including bisphosphonate use. PubMed Central (NIH). Systematic review and meta-analysis (peer-reviewed).
- ADA MouthHealthy implants overview: dental implants as an effective, long-term option for replacing missing teeth, with patient-facing what-to-expect context for this YMYL medical page. American Dental Association (MouthHealthy). Patient-facing professional association reference.
- FDA, Dental Implants: What You Should Know: general implant safety, materials, healing-time, and lifestyle (including smoking) context for this YMYL medical page. U.S. Food and Drug Administration. Federal regulator patient guidance.
Medically reviewed by Dr. Henry Qiu, DDS. Sources are professional society guidance, peer-reviewed systematic reviews, and recognized health authorities. Population estimates describe groups; your individual MRONJ risk is determined at consultation.